image: Figure 1: DUSP4 is a selective dependency in BRAFV600E mutant cancer cell lines. (A) DUSP4- and BRAF-dependent cell lines are enriched in the BRAFV600E mutant cluster. Gene dependency data of the DUSP paralog family and BRAF originates from the DepMap Consortium database. Columns represent the genes; rows represent the cell lines; dependency Chronos scores are depicted in the tiles, ranging from red (no dependency) to blue (dependency). The dark turquoise annotation bar indicates the BRAFV600E mutant cell lines; the grey annotation bar for BRAF non-V600E mutation carrying cell lines. (B) Proliferation effects after DUSP4 CRISPR depletion in BRAFV600E mutant COLO 201 and HS695T cell lines and in BRAF wild-type A549 cell line measured as GFP signal normalized to day 3 post DUSP4 CRISPR guide transduction. 2 biological replicates are shown. Strong proliferation defects are detected in BRAFV600E mutant cell lines only. BRAFV600E cell lines remain DUSP4 dependent in a BRAF inhibitor resistant setting. (C) Proliferation effect after DUSP4 CRISPR depletion and DUSP4 overexpression or 1 nM trametinib treatment in BRAFV600E mutant COLO 201 and HS695T cell lines. The proliferation effect is measured as GFP signal normalized to day 3 post DUSP4 CRISPR guide transduction. 2 biological replicates are shown. The DUSP4 proliferation effect can be partially rescued by DUSP4 overexpression and completely rescued by MAPK pathway inhibition upstream of DUSP4. (D) Proliferation effect after CRISPR depletion of DUSP paralogs DUSP1, DUSP5 and DUSP6 measured as GFP signal normalized to day 3 post DUSP CRISPR guide transduction. DUSP1, DUSP5 or DUSP6 depletion does not cause a proliferation effect in COLO 201 and HS695T cell lines.
Credit: Copyright: © 2026 Hopfgartner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
“These results suggest limited efficacy of DUSP4 inhibition in monotherapy.”
BUFFALO, NY - November 10, 2026 – A new research paper was published in Volume 17 of Oncotarget on November 5, 2026, titled “Limitation of the therapeutic potential of DUSP4 through adaptive feedback partially mediated by DUSP5.”
The study explores whether targeting a protein called DUSP4 could help control cancer growth. Researchers found that reducing DUSP4 activity slowed tumor growth in experimental models, but an adaptive response involving a related protein, DUSP5, appeared to limit its therapeutic potential.
The study was co-first-authored by Barbara Hopfgartner and Monika Kriz, who contributed equally to the research, alongside Donat Alpar, Yvonne Westermaier, Marco H. Hofmann, Ralph A. Neumüller and Sarah Grosche. All authors are affiliated with Boehringer Ingelheim RCV GmbH & Co KG in Vienna, Austria. Neumüller and Grosche are the corresponding authors.
Cancer cells depend on molecular signals to grow and divide. One important signaling network, known as the MAPK pathway, is frequently altered in cancer. While many existing treatments aim to block excessive MAPK activity, researchers are also investigating whether increasing this activity beyond tolerable levels could interfere with cancer cell growth.
DUSP4 helps regulate the MAPK pathway by limiting the activity of ERK proteins. In cancers carrying the BRAF V600E mutation, DUSP4 may help prevent excessive signaling, making it a potential therapeutic target.
To explore this possibility, the researchers used genetic approaches to reduce DUSP4 activity in colorectal cancer and melanoma cell models, including cells resistant to the BRAF inhibitor dabrafenib. They found that DUSP4 reduction increased MAPK signaling and slowed cancer cell proliferation. In colorectal cancer cells, it also caused cell cycle arrest, preventing cells from progressing normally toward division.
The team then examined the effects of DUSP4 reduction in mice bearing colorectal tumors. Although tumor growth was significantly inhibited, the tumors remained largely stable rather than shrinking. Signs of regrowth also appeared during the experiment, suggesting that cancer cells could adapt to the disruption.
Further investigation revealed that reducing DUSP4 increased the expression of DUSP5, a related protein that also regulates MAPK signaling. In additional cell experiments, higher DUSP5 levels helped compensate for DUSP4 loss and restored cancer cell proliferation to varying degrees.
These findings suggest that cancer cells may adjust their signaling networks to counteract the effects of DUSP4 reduction. This compensatory response could help explain why targeting DUSP4 alone may not produce lasting tumor regression.
“This points to context-specific genetic buffering among DUSP proteins.”
The results highlight an important challenge in developing treatments that disrupt cancer cell signaling. Even when a potential target is successfully suppressed, cancer cells may activate alternative mechanisms that reduce the treatment's effectiveness.
However, the findings are based on preclinical experiments involving cancer cell lines and mouse models. They do not establish how DUSP4-targeted therapies would perform in patients, and further research is needed to determine their clinical potential.
Overall, the study provides insight into how DUSP5-related feedback may limit the therapeutic potential of DUSP4. Understanding these adaptive responses could help guide future research into more effective strategies for controlling cancer growth.
DOI: https://doi.org/10.18632/oncotarget.28923
Correspondence to: Ralph A. Neumüller - ralph.neumueller@boehringer-ingelheim.com, Sarah Grosche - sarah.grosche@boehringer-ingelheim.com
Abstract video: https://www.youtube.com/watch?v=0TMvuD5wJvw
Keywords: signaling, DUSP4, MAPK, cancer, biology
Click here to sign up for free Altmetric alerts about this article.
________
To learn more about the journal, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
Journal
Oncotarget
Method of Research
News article
Subject of Research
Cells
Article Title
Limitation of the therapeutic potential of DUSP4 through adaptive feedback partially mediated by DUSP5
Article Publication Date
5-Nov-2026
COI Statement
All authors are full-time employees at Boehringer Ingelheim RCV.